OpenEvidence, the "ChatGPT for doctors," recently secured $250M, elevating its valuation to $12B. Th...
The AMW Read
OpenEvidence introduces a new top-tier vertical entrant with a $12B valuation and massive $100M ARR, satisfying the cross.§D threshold (> $5B valuation).
NoveltySignificance
Healthcare & Bio · Player MapCapital Cycles
OpenEvidence, the "ChatGPT for doctors," recently secured $250M, elevating its valuation to $12B. This remarkable leap from $6B in October is fueled by over $100M in annual revenue from healthcare subscriptions. The AI platform provides crucial evidence-based medical insights, significantly enhancing physician efficiency and transforming patient care. This surge highlights the growing demand for specialized, reliable AI solutions in healthcare.
#AIinHealthcare #HealthTech #OpenEvidence #StartupGrowth
